
Claims

1. A compound of formula (I):



I,


wherein:

R_1 is H or F,

R_2 is H or F,

R_3 is -C(O)-Het1,

wherein -C(O)-Het1 is:



,

wherein:

E is O or S;

R^0 is independently selected from the group consisting of $(C_1$-$C_4)$alkyl, -O-$(C_1$-$C_4)$alkyl, - COO-$(C_1$-$C_4)$alkyl, F, Cl, Br, I, OH, COOH, and CN; and



m is selected from the group consisting of 0, 1, and 2;

R^4 is selected from the group consisting of H, Cl, Br, F, and $(C_1$-$C_2)$alkyl;

one of R^5, R^6, and R^7 is R^8-L–, and the other two of R^5, R^6, and R^7 are each independently selected from the group consisting of H, (C_1-C_4)alkyl, -O-(C_1-C_4)alkyl, -O-(C_1-C_3)alkylidene-(C_6)aryl, F, Cl, Br, and O-CF_3; and


R^8-L– is R^8–Lin4-Lin3-Lin2-Lin1–,

wherein:

Lin1 is selected from the group consisting of , , -O-, -N(CH_3)-, and ⁞- (C_1-C_4)alkylidene-C(O)NH—≀,

wherein in Lin1:



Y is CH or N;

⁞- indicates attachment to Lin2, and when Lin1 is , Lin2 is in *meta*- or *para*-position to —≀ and



—≀ indicates attachment to the quinoline;

R^9 is selected from the group consisting of halogen, CO_2H, (C_1-C_6)alkyl, hydroxy substituted (C_1-C_6)alkyl, and -O-(C_1-C_6)alkyl; and

n is selected from the group consisting of 0, 1, and 2, preferably n is 0 or 1, more preferably n is 0;

Lin2 is selected from the group consisting of -C(O)-NH-, -NH-C(O)-, and -$S(O)_2$- when Lin1 is selected from the group consisting of , , and ⁞- (C_1-C_4)alkylidene-C(O)NH—≀, and Lin2 is absent when Lin1 is -O- or –N(CH_3)-;

Lin3 is (C_2-C_4)alkylidene;



Lin4 is selected from the group consisting of -NR^{10}, , and ,

wherein in Lin4:



 indicates attachment to Lin3,

indicates the attachment to R_8;


R^{10} is selected from the group consisting of H, CH_2-COOH, and (C_1-C_4)alkyl; and


 is optionally oxidized to ;

R^8 is a chelator or a cytotoxic agent; and

wherein  in formula (I) may optionally be oxidized to its N-oxide .

2. The compound of Claim 1, wherein -C(O)-Het1 is selected from the group consisting of:





, , , and , ,

wherein:

E is O or S; and

R^0 is selected from the group consisting of -CH_3, -O-CH_3, -$COOCH_3$, F, Cl, and Br; and

preferablythe compound has a structure of formula (II):



II.


3. The compound of any one of Claims 1, and 2, wherein R^4 is H or -CH_3.

4. The compound of any one of Claims 1, 2, and 3, wherein R^6 is R^8-L; preferably R^5 and R^7 are each independently selected from the group consisting of H and -CH_3.

5. The compound of any one of Claims 1, 2, and 3, wherein R^7 is R^8-L; preferably R^5 and R^6 are each independently selected from the group consisting of H and -CH_3.


6. The compound of any one of Claims 1, 2, 3, 4, and 5 preferably of any one of Claims 2, 3, 4, and 5, wherein Lin1 is




or 

.


7. The compound of any one of Claims 1, 2, 3, 4, 5, and 6, wherein Lin1 is





; preferably Y is CH; more preferably


Lin1 is 

.

8. The compound of any one of Claims 1, 2, 3, 4, 5, and 6, preferably any one of Claims 2, 3, 4, 5, and 6, wherein Lin2-Lin1 is selected from the group consisting of 





, 


, and 


,

wherein

 indicates attachment to the quinoline and  indicates attachment to Lin3; preferably Lin2-Lin1 is selected from the group consisting of 

, 

, 















, and 


, wherein

 indicates attachment to the quinoline and  indicates attachment to Lin3.


9. The compound of any one of Claims 1, 2, 3, 4, 5, 6, 7, and 8, preferably any one of Claims 2, 3, 4, 5, 6, 7, and 8, wherein Lin3 is –(C_2-C_3)alkylidene.

10. The compound of any one of Claims 1, 2, 3, 4, and 5, wherein R^8-L- is selected from the group consisting of:














, and ; preferably R^8-L- is selected from the group consisting of:



R^8-L- is selected from the group consisting of:




11. The compound of any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, wherein R^8 is a chelator.


12. The compound of Claim 11, wherein the chelator is selected from the group consisting of DOTA, DOTAGA, NOPO, PCTA, NOTA, NODAGA, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, DFO, Macropa, DOTAM, HOPO, TRAP, THP, DATA, NOTP, sarcophagine, FSC, NETA, H4octapa, Pycup, N_xS_{4-x} (N4, N2S2, N3S), Hynic, $^{99m}Tc(CO)_3$-Chelators, more preferably DOTA, DOTAGA, NOPO, PCTA, DOTAM, Macropa, NOTA, NODAGA, NODA-MPAA, HBED, CB-TE2A, DFO, THP, N4 and most preferably DOTA, DOTAGA, NOPO, PCTA, DOTAM, Macropa, NOTA, and NODAGA; preferably the chelator is selected from the group consisting of DOTA, DOTAM, Macropa, NOTA, and NODAGA.

13. The compound of any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, wherein R^8 is a cytotoxic agent.


14. The compound of Claim 1, wherein the compound is selected from the group consisting of




3BP-3412




3BP-3581




3BP-3582




3BP-4663




3BP-4664




3BP-4665




3BP-4694




3BP-4808



3BP-4809



3BP-4810 and



3BP-4811 .

15. The compound of any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the compound comprises a diagnostically active nuclide and/or a therapeutically active

nuclide, preferably the diagnostically active nuclide is a diagnostically active radionuclide and the therapeutically active nuclide is a therapeutically active radionuclide.

16. A composition, preferably a pharmaceutical composition, wherein the composition comprises the compound according to any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15, and a pharmaceutically acceptable excipient.

17. Use of a compound of claim 15 in the manufacture of a medicament for the treatment and/or prevention of a disease, wherein the disease is a disease mediated by or a disease involving fibroblast activation protein (FAP).

18. Use of a compound of claim 15 in the manufacture of a medicament for the diagnosis of a disease, wherein the disease is a disease mediated by or a disease involving fibroblast activation protein (FAP).

19. The use of any one of claims 17 to 18, wherein the disease involving fibroblast activation protein (FAP) is a disease where cells express fibroblast activation protein.

20. The use of claim 19, wherein the cells express fibroblast activation protein (FAP) in an upregulated manner.

21. The use of any one of claims 17 to 20, wherein the disease involves diseased tissue containing cells showing upregulated expression of FAP.

22. The use of any one of claims 19 to 21, wherein the cells are fibroblast activation protein (FAP) expressing fibroblasts.

23. The use of claim 22, wherein the fibroblast activation protein expressing fibroblasts (FAP) are cancer associated fibroblasts.

24. The use of any one of claim 17 to 23, wherein the disease is a neoplasm.

25. The use of claim 24, wherein the neoplasm is a cancer or a tumor.

26. The use of any one of claims 17 to 25, wherein the disease is selected from the group comprising a solid tumor, an epithelial tumor, a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, a cholangiocarcinoma, an endometrial cancer, an esophageal cancer, a gastric cancer, a gastrointestinal stromal tumors, a head and neck cancer, a liver cancer, a lung cancer, a melanoma, a mesothelioma, a neuroendocrine tumor and carcinoma, an ovarian cancer, a pancreatic cancer, a prostate cancer, a renal cell carcinoma, a salivary carcinoma, a sarcoma, a squamous cell carcinoma, a thyroid cancer, and combinations thereof.

27. The use of any one of claims 17 to 22, wherein the disease is selected from the group comprising an inflammatory disease, a cardiovascular disease, an autoimmune disease and a fibrotic disease.

28. The use of any one of claims 17 to 22, wherein the disease is selected from the group comprising atherosclerosis, arthritis, rheumatoid arthritis, cardiovascular disease involving atherosclerotic plaques, atherosclerotic pathology caused by rupture of plaques, acute coronary syndrome, myocardial infarction, thrombosis, or vessel occlusion, idiopathic pulmonary fibrosis, Crohn’s disease, and liver fibrosis.